dc.contributor.author | Chakera, Ali J. | |
dc.contributor.author | Spyer, Gill | |
dc.contributor.author | Vincent, Nicola | |
dc.contributor.author | Ellard, Sian | |
dc.contributor.author | Hattersley, Andrew T. | |
dc.contributor.author | Dunne, Fidelma P. | |
dc.date.accessioned | 2018-09-20T16:02:59Z | |
dc.date.available | 2018-09-20T16:02:59Z | |
dc.date.issued | 2014-02-18 | |
dc.identifier.citation | Chakera, Ali J. Spyer, Gill; Vincent, Nicola; Ellard, Sian; Hattersley, Andrew T.; Dunne, Fidelma P. (2014). The 0.1% of the population with glucokinase monogenic diabetes can be recognized by clinical characteristics in pregnancy: the atlantic diabetes in pregnancy cohort. Diabetes Care 37 (5), 1230-1236 | |
dc.identifier.issn | 0149-5992,1935-5548 | |
dc.identifier.uri | http://hdl.handle.net/10379/10735 | |
dc.description.abstract | OBJECTIVEIdentifying glucokinase monogenic diabetes (GCK-MODY) in pregnancy is important, as management is different from management for other forms of gestational diabetes mellitus (GDM) and there is no increased maternal risk of type 2 diabetes. We calculated the population prevalence of GCK-MODY in pregnancy and determined the clinical characteristics that differentiate pregnant women with GCK-MODY from those with GDM.RESEARCH DESIGN AND METHODSWe calculated the population prevalence of GCK-MODY in pregnancy by testing a subset of patients from the population-based Atlantic Diabetes in Pregnancy (Atlantic DIP) study (n = 5,500). We sequenced for GCK mutations in 247 women with a fasting glucose 5.1 mmol/L and 109 randomly selected control subjects with normal fasting glucose. Using data from the cases found and 40 previously identified GCK-MODY pregnancies, we analyzed whether clinical criteria could be used to differentiate GCK-MODY from GDM.RESULTSFour women with fasting glucose 5.1 mmol/L were diagnosed with GCK-MODY. No cases were identified with normal fasting glucose. The population prevalence of GCK-MODY is 1.1 in 1,000 (95% CI 0.3-2.9 in 1,000) and prevalence in GDM is 0.9% (95% CI 0.3-2.3). Fasting glucose and BMI significantly differentiate GCK-MODY from GDM (P < 0.0001). Combined criteria of BMI <25 kg/m(2) and fasting glucose 5.5 mmol/L has a sensitivity 68%, specificity 96%, and number needed to test of 2.7 women with GDM to find one case of GCK-MODY.CONCLUSIONSOur large population cohort of pregnant women tested estimates the population prevalence of GCK-MODY of 1.1 in 1,000. We have shown routine clinical criteria that can identify which women should be tested for GCK-MODY in pregnancy. | |
dc.publisher | American Diabetes Association | |
dc.relation.ispartof | Diabetes Care | |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 Ireland | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/3.0/ie/ | |
dc.subject | high prevalence | |
dc.subject | mutations | |
dc.subject | gene | |
dc.subject | mellitus | |
dc.subject | young | |
dc.subject | women | |
dc.subject | criteria | |
dc.subject | glucose | |
dc.subject | mody | |
dc.subject | gck | |
dc.title | The 0.1% of the population with glucokinase monogenic diabetes can be recognized by clinical characteristics in pregnancy: the atlantic diabetes in pregnancy cohort | |
dc.type | Article | |
dc.identifier.doi | 10.2337/dc13-2248 | |
dc.local.publishedsource | http://care.diabetesjournals.org/content/diacare/37/5/1230.full.pdf | |
nui.item.downloads | 0 | |